Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Extracellular Vesicles | 3 | 2017 | 607 | 0.62 | Why? |
| Blood Coagulation Tests | 7 | 2020 | 855 | 0.60 | Why? |
| Drug Resistance, Neoplasm | 1 | 2017 | 447 | 0.52 | Why? |
| Blood Coagulation | 8 | 2019 | 2768 | 0.44 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.42 | Why? |
| Factor Xa Inhibitors | 3 | 2019 | 490 | 0.37 | Why? |
| Thromboxane-A Synthase | 1 | 2006 | 2 | 0.33 | Why? |
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2006 | 4 | 0.32 | Why? |
| Prostaglandins | 1 | 2006 | 21 | 0.32 | Why? |
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 48 | 0.30 | Why? |
| Benzamides | 2 | 2019 | 421 | 0.30 | Why? |
| Immunoassay | 4 | 2021 | 4485 | 0.28 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.27 | Why? |
| Thrombin | 4 | 2020 | 325 | 0.27 | Why? |
| Hemostasis | 2 | 2020 | 811 | 0.27 | Why? |
| Pyridines | 2 | 2019 | 680 | 0.24 | Why? |
| Anticoagulants | 8 | 2020 | 9563 | 0.22 | Why? |
| Sulfonamides | 2 | 2006 | 1294 | 0.19 | Why? |
| Thromboxane B2 | 1 | 2018 | 23 | 0.19 | Why? |
| Spectrum Analysis | 1 | 2019 | 112 | 0.19 | Why? |
| Drug Dosage Calculations | 1 | 2020 | 243 | 0.19 | Why? |
| Carbon Compounds, Inorganic | 1 | 2017 | 1 | 0.19 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.18 | Why? |
| Silicon Compounds | 1 | 2017 | 4 | 0.18 | Why? |
| HL-60 Cells | 1 | 2017 | 60 | 0.18 | Why? |
| Gene Expression Regulation, Leukemic | 1 | 2017 | 31 | 0.18 | Why? |
| Antibodies, Viral | 12 | 2021 | 51949 | 0.18 | Why? |
| Multidrug Resistance-Associated Proteins | 1 | 2017 | 29 | 0.18 | Why? |
| Disseminated Intravascular Coagulation | 2 | 2017 | 994 | 0.18 | Why? |
| Factor X | 1 | 2017 | 18 | 0.17 | Why? |
| Thrombosis | 5 | 2021 | 7504 | 0.17 | Why? |
| Capnocytophaga | 1 | 2017 | 18 | 0.17 | Why? |
| Serotonin | 1 | 2018 | 137 | 0.17 | Why? |
| Platelet Activation | 2 | 2018 | 660 | 0.16 | Why? |
| Drug Resistance, Multiple | 1 | 2017 | 156 | 0.16 | Why? |
| Partial Thromboplastin Time | 4 | 2019 | 436 | 0.15 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 116 | 0.15 | Why? |
| Thrombocytopenia | 2 | 2021 | 2093 | 0.15 | Why? |
| Bites and Stings | 1 | 2017 | 91 | 0.15 | Why? |
| Blood Preservation | 1 | 2017 | 191 | 0.15 | Why? |
| Dabigatran | 1 | 2017 | 204 | 0.15 | Why? |
| Blood Chemical Analysis | 1 | 2019 | 541 | 0.14 | Why? |
| European Union | 1 | 2018 | 565 | 0.14 | Why? |
| Blood Platelets | 3 | 2018 | 1704 | 0.13 | Why? |
| Heparin | 2 | 2017 | 2600 | 0.13 | Why? |
| Pharmacovigilance | 1 | 2018 | 501 | 0.13 | Why? |
| Drug Monitoring | 2 | 2020 | 1408 | 0.13 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.13 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 694 | 0.13 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 877 | 0.12 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.12 | Why? |
| Leukemia | 1 | 2017 | 598 | 0.11 | Why? |
| Immunoglobulin A | 2 | 2020 | 3567 | 0.11 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2018 | 669 | 0.11 | Why? |
| Erythrocytes | 1 | 2017 | 617 | 0.11 | Why? |
| Nanostructures | 1 | 2017 | 700 | 0.10 | Why? |
| Intracranial Hemorrhages | 1 | 2018 | 1170 | 0.10 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.10 | Why? |
| Peptide Hydrolases | 1 | 2017 | 1269 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.09 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.09 | Why? |
| Kinetics | 3 | 2020 | 3238 | 0.09 | Why? |
| Prothrombin Time | 2 | 2019 | 434 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.08 | Why? |
| Thromboxane A2 | 1 | 2006 | 17 | 0.08 | Why? |
| Cyclooxygenase 1 | 1 | 2005 | 20 | 0.08 | Why? |
| Time Factors | 8 | 2021 | 31397 | 0.08 | Why? |
| Administration, Oral | 3 | 2018 | 2340 | 0.08 | Why? |
| Tissue Distribution | 2 | 2017 | 483 | 0.07 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 9335 | 0.07 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.07 | Why? |
| Luminescent Measurements | 2 | 2020 | 924 | 0.07 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.07 | Why? |
| Nanoparticles | 1 | 2017 | 2040 | 0.07 | Why? |
| Humans | 37 | 2021 | 930598 | 0.07 | Why? |
| Drug Administration Schedule | 2 | 2021 | 2324 | 0.06 | Why? |
| Platelet Aggregation | 1 | 2006 | 318 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.06 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.06 | Why? |
| Neovascularization, Pathologic | 1 | 2006 | 305 | 0.06 | Why? |
| Sensitivity and Specificity | 5 | 2020 | 22971 | 0.06 | Why? |
| Reproducibility of Results | 4 | 2020 | 11304 | 0.06 | Why? |
| Rats | 3 | 2017 | 2764 | 0.06 | Why? |
| Cardiology | 1 | 2016 | 2873 | 0.06 | Why? |
| Aerosols | 1 | 2017 | 5393 | 0.05 | Why? |
| Biological Variation, Individual | 1 | 2020 | 66 | 0.05 | Why? |
| Diabetic Retinopathy | 1 | 2006 | 347 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.05 | Why? |
| Male | 18 | 2021 | 367725 | 0.05 | Why? |
| Societies, Medical | 1 | 2016 | 6907 | 0.05 | Why? |
| Cardiovascular Diseases | 1 | 2005 | 11497 | 0.05 | Why? |
| Female | 18 | 2021 | 380317 | 0.05 | Why? |
| Education, Medical | 1 | 2016 | 2461 | 0.05 | Why? |
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 162 | 0.05 | Why? |
| Luminescence | 1 | 2020 | 236 | 0.05 | Why? |
| Biological Availability | 1 | 2020 | 388 | 0.05 | Why? |
| Freezing | 1 | 2019 | 106 | 0.05 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.05 | Why? |
| Structure-Activity Relationship | 1 | 2006 | 2219 | 0.05 | Why? |
| Spectrometry, X-Ray Emission | 1 | 2017 | 21 | 0.05 | Why? |
| Diuretics | 1 | 2000 | 326 | 0.05 | Why? |
| Calibration | 1 | 2019 | 307 | 0.04 | Why? |
| Adult | 12 | 2021 | 244371 | 0.04 | Why? |
| Thrombin Time | 1 | 2017 | 46 | 0.04 | Why? |
| Metabolic Clearance Rate | 1 | 2017 | 110 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Spectrometry, Mass, Electrospray Ionization | 1 | 2018 | 159 | 0.04 | Why? |
| Polycarboxylate Cement | 1 | 2017 | 12 | 0.04 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.04 | Why? |
| Factor Xa | 1 | 2018 | 113 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Atherosclerosis | 1 | 2006 | 768 | 0.04 | Why? |
| Monte Carlo Method | 1 | 2020 | 577 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.04 | Why? |
| Histone Deacetylases | 1 | 2017 | 37 | 0.04 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Electrochemical Techniques | 1 | 2020 | 406 | 0.04 | Why? |
| Catalysis | 1 | 2017 | 253 | 0.04 | Why? |
| Protein Stability | 1 | 2019 | 756 | 0.04 | Why? |
| Reference Values | 1 | 2019 | 795 | 0.04 | Why? |
| Surface Properties | 1 | 2017 | 448 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2019 | 536 | 0.04 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.04 | Why? |
| Platelet Function Tests | 1 | 2017 | 231 | 0.04 | Why? |
| Vitamin K | 1 | 2018 | 263 | 0.04 | Why? |
| Fibrinolysis | 1 | 2020 | 521 | 0.04 | Why? |
| Nucleocapsid | 1 | 2020 | 734 | 0.04 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.04 | Why? |
| Aged | 9 | 2021 | 215776 | 0.04 | Why? |
| Quality Control | 1 | 2019 | 628 | 0.04 | Why? |
| Blood Specimen Collection | 1 | 2019 | 387 | 0.04 | Why? |
| Enzyme Inhibitors | 1 | 2006 | 1881 | 0.04 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.04 | Why? |
| Transfusion Reaction | 1 | 2017 | 245 | 0.03 | Why? |
| Belgium | 1 | 2021 | 2064 | 0.03 | Why? |
| Rats, Sprague-Dawley | 1 | 2017 | 987 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Animals | 6 | 2017 | 78931 | 0.03 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.03 | Why? |
| Drug Design | 1 | 2006 | 2627 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2020 | 9893 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Erythrocyte Transfusion | 1 | 2017 | 386 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.03 | Why? |
| Particle Size | 1 | 2017 | 1052 | 0.03 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| RNA, Small Interfering | 1 | 2017 | 817 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.02 | Why? |
| Myocardial Infarction | 1 | 2006 | 3361 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Plasma | 1 | 2019 | 1809 | 0.02 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.02 | Why? |
| Swine | 1 | 2017 | 3352 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Continuity of Patient Care | 1 | 2018 | 1574 | 0.02 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Mice | 2 | 2017 | 21357 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Arthritis, Rheumatoid | 1 | 2020 | 2043 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2005 | 10649 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Protein Domains | 1 | 2017 | 6563 | 0.02 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.02 | Why? |
| Neoplasms | 2 | 2017 | 17251 | 0.02 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Isomerism | 1 | 2000 | 13 | 0.01 | Why? |
| Crystallography | 1 | 2000 | 52 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Europe | 1 | 2016 | 12702 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Molecular Conformation | 1 | 2000 | 374 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Quantitative Structure-Activity Relationship | 1 | 2000 | 209 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Lung | 1 | 2017 | 31049 | 0.01 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.01 | Why? |